ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Open Access
- 9 September 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (20) , OF1-OF12
Abstract
Purpose: ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood. Experimental Design: The clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients. Results: ARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4. Conclusions: The combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82272786, 82272930, 82372793, 82373276)
- China Postdoctoral Science Foundation (BX20230091, 2024M760547)
- Natural Science Foundation of Shanghai Municipality (22ZR1413400, 23ZR1440300, 23ZR1411700, 24SF1901304)
- Shanghai Sailing Program (24YF2705400, 24YF2706000)
- Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission (24CGA07)
- Shanghai Municipal Health Bureau (202340127, 202340195, 20224Y0232)
- Beijing Xisike Clinical Oncology Research Foundation (Y-Gilead2024-PT-0098)
- Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201802)
- Shanghai Anticancer Association EYAS Project (SACA-CY22B02, ZYJH202309, SACA-CY24C10)
- Youth Foundation of Zhongshan Hospital affiliated with Fudan University (ZSZP202405)
- Chongqing Postdoctoral Program for Innovative Talents (CQBX202426)
- Key Project of Young Doctor Incubation Program of the Second Affiliated Hospital of Army Medical University (2024YQB024)
This publication has 50 references indexed in Scilit:
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEuropean Urology, 2017
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint BlockadeCell Reports, 2017
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialThe Lancet, 2017
- Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expressionGenome Biology, 2016
- ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinomaHuman Pathology, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladderHuman Pathology, 2014
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010